Orion Biotech Opportunities Performance
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Orion Biotech are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Orion Biotech Opportunities has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong forward indicators, Orion Biotech is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Orion |
Orion Biotech Relative Risk vs. Return Landscape
If you would invest (100.00) in Orion Biotech Opportunities on October 19, 2025 and sell it today you would earn a total of 100.00 from holding Orion Biotech Opportunities or generate -100.0% return on investment over 90 days. Orion Biotech Opportunities is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Orion, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Orion Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orion Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Orion Biotech Opportunities, and traders can use it to determine the average amount a Orion Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ORIA |
Based on monthly moving average Orion Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orion Biotech by adding Orion Biotech to a well-diversified portfolio.
Orion Biotech Fundamentals Growth
Orion Stock prices reflect investors' perceptions of the future prospects and financial health of Orion Biotech, and Orion Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orion Stock performance.
| Return On Asset | -0.0028 | |||
| Current Valuation | 249.91 M | |||
| Shares Outstanding | 20 M | |||
| Price To Earning | 60.43 X | |||
| Price To Book | 1.29 X | |||
| EBITDA | 8.76 M | |||
| Cash And Equivalents | 418.55 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 98.07 K | |||
| Book Value Per Share | (0.31) X | |||
| Cash Flow From Operations | (376.76 K) | |||
| Earnings Per Share | 0.35 X | |||
| Total Asset | 203.33 K | |||
| Retained Earnings | (7.79 K) | |||
Things to note about Orion Biotech Opport performance evaluation
Checking the ongoing alerts about Orion Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Orion Biotech Opport help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Orion Biotech Opport is not yet fully synchronised with the market data | |
| Orion Biotech Opport has some characteristics of a very speculative penny stock | |
| Orion Biotech Opport has a very high chance of going through financial distress in the upcoming years | |
| Orion Biotech Opportunities currently holds about 418.55 K in cash with (376.76 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Over 82.0% of the company shares are owned by institutional investors |
- Analyzing Orion Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orion Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Orion Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orion Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orion Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Orion Biotech's stock. These opinions can provide insight into Orion Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Orion Stock
If you are still planning to invest in Orion Biotech Opport check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orion Biotech's history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |